文献速递神经免疫认知障碍与痴呆

评估多发性硬化中脑容量损失的生物学和方法学问题

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2018-01-01

该研究纳入140例临床孤立综合征或多发性硬化患者,每年行MRI扫描,评估脑容量损失随病程的动态变化,并比较Jacobian积分与FSL(SIENA-X和FIRST)估计脑容量损失的可重复性和可交换性。结果显示多发性硬化发病后前5年脑容量损失率更高,FSL与JI在全脑容量损失上相关性高(R2=0.92),但在特定脑区相关性差,原文作者认为每年0.4%的脑容量损失阈值应重新考虑。

要点

  • 多发性硬化发病后前5年全脑容量变化R2=0.65、灰质容量变化R2=0.52,损失率更高。
  • 全脑容量损失JI与FSL相关性高(R2=0.92),但特定脑区相关性差。
  • JI对特定脑区容量损失的估计比FSL(SIENA-X和FIRST)更精确、偏差更小。

核心结论

  • 原文作者认为,由于多发性硬化病程中脑容量损失动态不同以及不同影像方法估计的可重复性和变异性有限,每年低于0.4%的脑容量损失阈值作为治疗有效标志应重新考虑。

研究设计与样本

  • 队列研究,纳入2011年2月至2015年10月间临床孤立综合征或多发性硬化患者140例,每年行MRI扫描。
  • 另用2组健康志愿者队列评估MRI测量的短期可重复性(n=34)和年度脑容量损失(n=20)。
  • 数据分析于2017年1月至5月进行。

主要发现

  • 140例患者中女性95例(67.9%),中位(四分位距)年龄40.7(33.6-48.1)岁,接受4次MRI扫描,中位(四分位距)扫描间隔364(351-379)天。
  • 34例健康志愿者中女性18例(53%),中位(四分位距)年龄33.5(26.2-42.5)岁,2次MRI扫描中位(四分位距)间隔24.5(0.0-74.5)天。
  • 20例健康志愿者中女性10例(50%),中位(四分位距)年龄33.0(28.7-39.2)岁,2次MRI扫描中位(四分位距)间隔384.5(366.3-407.8)天。
  • 多发性硬化发病后前5年脑容量损失率更高(全脑容量变化R2=0.65,灰质容量变化R2=0.52),与使用类固醇直接相关(β=0.280;P=0.02),与发病年龄呈负相关,尤其在前5年(β=0.015;P=0.047)。
  • JI与FSL(SIENA)在全脑容量损失的可重复性相似,JI对特定脑区容量损失的估计比FSL(SIENA-X和FIRST)更精确、偏差更小;全脑容量损失JI与FSL相关性高(R2=0.92),但特定脑区相关性差;全脑容量变化区分多发性硬化患者与健康志愿者的曲线下面积相似,但JI与FSL的阈值和准确度指数不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Before using brain volume loss (BVL) as a marker of therapeutic response in multiple sclerosis (MS), certain biological and methodological issues must be clarified. OBJECTIVES: To assess the dynamics of BVL as MS progresses and to evaluate the repeatability and exchangeability of BVL estimates with Jacobian Integration (JI) and Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL) (specifically, the Structural Image Evaluation, Using Normalisation, of Atrophy-Cross-Sectional [SIENA-X] tool or FMRIB's Integrated Registration and Segmentation Tool [FIRST]). DESIGN, SETTING, AND PARTICIPANTS: A cohort of patients who had either clinically isolated syndrome or MS was enrolled from February 2011 through October 2015. All underwent a series of annual magnetic resonance imaging (MRI) scans. Images from 2 cohorts of healthy volunteers were used to evaluate short-term repeatability of the MRI measurements (n = 34) and annual BVL (n = 20). Data analysis occurred from January to May 2017. MAIN OUTCOMES AND MEASURES: The goodness of fit of different models to the dynamics of BVL throughout the MS disease course was assessed. The short-term test-retest error was used as a measure of JI and FSL repeatability. The correlations (R2) of the changes quantified in the brain using JI and FSL, together with the accuracy of the annual BVL cutoffs to discriminate patients with MS from healthy volunteers, were used to measure compatibility of imaging methods. RESULTS: A total of 140 patients with clinically isolated syndrome or MS were enrolled, including 95 women (67.9%); the group had a median (interquartile range) age of 40.7 (33.6-48.1) years. Patients underwent 4 MRI scans with a median (interquartile range) interscan period of 364 (351-379) days. The 34 healthy volunteers (of whom 18 [53%] were women; median [IQR] age, 33.5 [26.2-42.5] years) and 20 healthy volunteers (of whom 10 [50%] were women; median [IQR] age, 33.0 [28.7-39.2] years) underwent 2 MRI scans within a median (IQR) of 24.5 (0.0-74.5) days and 384.5 (366.3-407.8) days for the short-term and long-term MRI follow-up, respectively. The BVL rates were higher in the first 5 years after MS onset (R2 = 0.65 for whole-brain volume change and R2 = 0.52 for gray matter volume change) with a direct association with steroids (β = 0.280; P = .02) and an inverse association with age at MS onset, particularly in the first 5 years (β = 0.015; P = .047). The reproducibility of FSL (SIENA) and JI was similar for whole-brain volume loss, while JI gave more precise, less biased estimates for specific brain regions than FSL (SIENA-X and FIRST). The correlation between whole-brain volume loss using JI and FSL was high (R2 = 0.92), but the same correlations were poor for specific brain regions. The area under curve of the whole-brain volume change to discriminate between patients with MS and healthy volunteers was similar, although the thresholds and accuracy index were distinct for JI and FSL. CONCLUSIONS AND RELEVANCE: The proposed BVL threshold of less than 0.4% per year as a marker of therapeutic efficiency should be reconsidered because of the different dynamics of BVL as MS progresses and because of the limited reproducibility and variability of estimates using different imaging methods.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Andorra M, Nakamura K, Lampert EJ, et al. Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurol. 2018. PMID: 29971335. doi:10.1001/jamaneurol.2018.1596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。